Review of Clinical Evidence for Delandistrogene Moxeparvovec for DMD

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Jessica Nance, MD, MS; Kimberly C. Chen, DO, MSHLM; Emma Ciafaloni, MD, FAAN; and Mary Pak, MD, FACP.

Haumschild engages Nance in a detailed exploration of the FDA’s accelerated approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy (DMD) in young patients. Nance navigates the complexities of trial design for DMD, emphasizing the challenge of demonstrating therapeutic efficacy amid the disease’s slow progression. She outlines the key factors considered for approval, including safety, target engagement, and functional outcomes. Through meticulous analysis of clinical trial data, Nance reveals significant increases in dystrophin expression and decreases in creatine kinase levels post treatment, indicating a positive impact on muscle integrity. However, the interpretation of functional outcomes posed challenges, particularly in older patients, highlighting the importance of age stratification in assessing treatment efficacy. Nance’s insights underscore the nuanced considerations involved in accelerated approval pathways for gene therapies, shedding light on the intricate balance between scientific evidence and clinical outcomes in pediatric DMD treatment.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.